233 The association between fetal growth restriction and advanced maternal age OBJECTIVE: Advanced maternal age (AMA) (35yo) has long been considered a risk factor for fetal growth restriction (FGR), however research regarding this topic is conflicting. The increasing rates of chronic disease that disproportionately affect older mothers make it difficult to assess the independent effect of maternal age. The objective of this study is to use the national CDC vital statistics database to determine the independent effect of maternal age on the rate of FGR. STUDY DESIGN: This was a retrospective cohort of women from the CDC National Vital Statistics System data from 2009 to 2013. All women aged 18yo-50yo delivering a singleton with a gestational age of 24-42 weeks were included. Women with fetal anomalies or aneuploidy were excluded. Women were categorized into 3 age groups at the time of delivery: 1) 18yo-34yo 2) 35yo-39yo 3) 40yo-50yo. The primary outcome of FGR at < 5 th and <10 th percentiles was compared among the three groups using a Chi-square test for categorical variables and a Kruskal-Wallis test for continuous variables. Multivariable logistic regression was done to determine whether maternal age group was associated with FGR. RESULTS: A total of 18,153,986 women were eligible for the analysis, of these 2,705,501 women were AMA. In univariate analysis, the rate of FGR both at the 5 th and at the 10 th percentiles was the lowest in the 35yo-39yo group (6.3% vs. 5.0% vs. 5.7% for group 1, 2 and 3 respectively, p<0.001 for FGR<5 th percentile and 11.6% vs. 9.21% vs. 10.1% for group 1, 2, and 3 respectively, p<0.001 for FGR<10 th percentile). In multivariable logistic regression, maternal age of 35yo-39yo continued to be associated with lower frequency of FGR both at the 5 th and at the 10 th percentiles (Tables 1 and 2 ). In contrast, maternal age of 40yo-50yo was associated with an increased frequency of FGR at the 5 th and at the 10 th percentiles (Tables 1 and 2) . CONCLUSION: Advanced maternal age of 40yo but not 35yo-39yo was associated with an increased risk of FGR. Our findings may have implications for routine sonographic growth surveillance in healthy women of advanced maternal age.
Poster Session I OBJECTIVE: Complete atrioventricular block (CAVB) occurs in 1-2% of SSA positive pregnancies and the consequences are significant: approximately 20% die and 50% require permanent cardiac pacing by 1 year of age. We hypothesize that dexamethasone (DEX) treatment for fetal anti-SSA/SSB antibody-mediated cardiac disease leads to better pregnancy outcome. Therefore, we assessed recent era experience of treatment with DEX of pregnancies with SSA/SSB-mediated fetal cardiac disease including all degrees of heart block on pregnancy, neonatal outcome and complication rates. STUDY DESIGN: We performed a retrospective multi-center cohort study of all SSA/SSB antibody positive pregnancies with fetal conduction system disease reported to the participating NAFTNet centers between January 2010 through December 2017. The primary outcomes included preterm delivery, maternal comorbidities, neonatal complications and secondary outcomes were, need for a pacemaker < 28 days, heart transplantation in the 1st year of life, and intrauterine or neonatal death in maternal/fetal days treated with DEX versus managed expectantly. RESULTS: There was a total of 101 SSA/SSB positive pregnancies of which 75 were treated with DEX and 26 were not. Of those treated, 49/75 (65%) met the primary outcome including 37 premature deliveries; 12 mothers developed comorbidities during treatment (4 with fetal growth restriction, 4 with oligohydramnios, 2 with new or worsening gestational diabetes, and 6 with mood disturbances). In comparison, in the untreated group 11/26 (42%) met the primary outcome of premature delivery. Regarding secondary outcomes, 32/75 (43%) dexamethasone-treated fetuses either required a pacemaker or had a fetal demise/died by 28 days of life, while 13/26 (50%) untreated met the secondary outcome of requiring pacemaker placement or fetal demise/dying prior to 28 days of life, while 1 infant required listing for cardiac transplantation. CONCLUSION: While the use of dexamethasone in SSA and SSB positive pregnancies is associated with a high rate of poor pregnancy outcomes, there was a similarly high rate in untreated SSA/SSB positive pregnancies suggesting that the maternal disease itself is influencing pregnancy complications. A trend suggesting that treatment decreases neonatal morbidity and progression of conduction disease deserves further study.
